| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Deferred offering costs | 273,528 | 175,226 |
| Net cash provided by financing activities | 23,753,351 | 6,643,535 |
| Net change in cash and cash equivalents | 8,283,141 | -2,148,966 |
| Cash and cash equivalents at beginning of period | 8,641,622 | - |
| Cash and cash equivalents at end of period | 16,924,763 | - |
ACTUATE THERAPEUTICS, INC. (ACTU)
ACTUATE THERAPEUTICS, INC. (ACTU)